Neuromodulation in the Elderly Depressed: a Brain Imaging Pilot Study

Neuromodulation in the Elderly Depressed: a Brain Im-aging Pilot Study

To evaluate safety and efficacy of an accelerated deep brain Transcranial Magnetic stimulation (adTMS) and transcutaneous direct current stimulation (tDCS) protocol in an elderly depressed patient population

Study Overview

• Status: Recruiting
• Conditions: Depressive Disorder, Treatment-Resistant; Old Age
• Intervention / Treatment: Device: a Magstim Rapid2 Plus1 Magnetic Stimulator connected to a Brainsway H1 coil

Detailed Description

With a growing number of elderly persons, geriatric depression - associated with important morbidity and mortality- is becoming a significant health problem. Given the risk of polypharmacy and increased side effects, alternative non pharmaceutical treatments such as repetitive transcranial magnetic stimulation (rTMS) and transcutaneous direct current stimulation (tDCS) may offer a solution. Given our recent positive results with accelerated rTMS in the elderly depressed, we want to continue to develop non-invasive treatment stimulations. The FDA approved deep brain TMS (dTMS) technique may be a promising option, targeting the brain underneath the neocortex with potentially better response and remission rates. Therefore, in a sham-controlled randomized controled trial, we will treat 44 geriatric depressed patients with accelerated dTMS (5 sessions/day over 4 days only), and evaluate clinical efficacy and safety. One week after the last adTMS or sham treatment, all patients will have access to active treatment in a 3 week open label transcutaneous direct current stimulation (tDCS) with a home-use device. In this manner we can examine clinnical effect of tDCS in the adTMS-sham group as well as the possible maintenance effect of tDCS in the adTMS active treatment group. Because new introduced neuromodulation paradigms should be rigorously neurobiologically examined before applying them on a regular basis, this research will include multimodal brain imaging techniques to elucidate the working mechanisms of these applications in order to optimize response prediction and treatment. Gut microbes can influence human metabolism, nutrition, physiology and immune status. The "microbiota-gut-brain axis" entails a continues exchange of information between the gut and central nervous system. Several clinical and preclinical studies have emphasized the bidirectional role of microbiome disruption in depression and depression-like behavior. In the current project, we also will examine the effects of neurostimulation treatments on the gut microbiome.

• Study Type: Interventional
• Enrollment (Anticipated): 44
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Dieter Zeeuws, MD; Phone Number: +324763459; Email: dieter.zeeuws@uzbrussel.be
• Study Contact Backup: Name: Chris Baeken, MD Phd; Phone Number: +324776425; Email: Chris.Baeken@uzbrussel.be

Study Locations

• Belgium
  • Brussels
    • Jette, Brussels, Belgium, 1090
      • Recruiting
      • UZ Brussel
      • Contact: Dieter Zeeuws, MD; Phone Number: +324777722; Email: dieter.zeeuws@uzbrussel.be
      • Contact: Chris Baeken, MD PhD; Phone Number: 324776425; Email: Chris.baeken@uzbrussel.be

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 65 years and older (OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• • In- and outpatients (age 65 year or older).

  • Meeting the Diagnostic and Statistical Manual of Mental Disorders (DSM 5) criteria for unipolar depression according 17-item Hamilton depression rating scale (HDRS-17) score of 17 or more.
  • Failed to respond to at least one adequate course with an antidepressant medication trial, including the current one.
  • Intention to continue the current (>6 weeks) antidepressant treatment at a stable dose dur-ing the stimulation.
  • Benzodiazepines are permitted up to a maximum dose of 40 mg diazepam or equivalent. If the dosage has been recently changed, it should be stable for at least 2 weeks.
  • Able to read, understand and sign the Informed Consent Form.

Exclusion Criteria:

• • Psychosis (except depression with psychotic features).

  • A personal history of seizures or epilepsy, a history of seizures or epilepsy in first degree relatives and the presence of any known factor that can lower the seizure threshold (sleep deprivation, substance abuse, etc.), previous head injury and the presence of metallic implants in the cephalic region (e.g., aneurysm clips, shunts, stimulators, cochlear implants, electrodes) with the exception of dental fillings. The presence of cardiac pacemakers, neurostimulators, surgical clips or other electronic equipment, comorbidity with the following neurological disorders: increased intracranial pressure, space-occupying lesion, history of stroke or transient ischemic attack, brain aneurysm and any structural brain damage with increased risk for epilepsy detected with (study related) MRI.
  • Patients with cognitive disturbances or dementia (Mini Mental State) < 24.
  • Suicide attempt within 6 months before the start of the study or present high risk of suicide per the investigator's clinical judgment and indicative response* on the Columbia-Suicide Severity Rating Scale (C-SSRS) and 21-items Beck Scale for Suicide Ideation (BSI). *'yes' on Item 5 (active suicidal ideation with specific plan and intent).
  • Any change in the habitual psychopharmacological agents will be considered as dropout.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: RANDOMIZED
• Interventional Model: PARALLEL
• Masking: QUADRUPLE

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
ACTIVE_COMPARATOR: Active adTMS; Subjects in the treatment arm receive 20 sessions of real adTMS . The sessions will be spread over the four succeeding days (5 sessions daily on Tuesday, Wednesday, Thursday and Friday).	Device: a Magstim Rapid2 Plus1 Magnetic Stimulator connected to a Brainsway H1 coil; 3 weeks home use; Other Names: Sooma tDCS (open label)
SHAM_COMPARATOR: Sham adTMS; Subject in the control/Placebo/Sham arm receive 20 sessions of sham adTMS. The sessions will be spread over the four succeeding days (5 sessions daily on Tuesday, Wednesday, Thursday and Friday).	Device: a Magstim Rapid2 Plus1 Magnetic Stimulator connected to a Brainsway H1 coil; 3 weeks home use; Other Names: Sooma tDCS (open label)

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Clinical effect of adTMS (Changes in depression severity clinician-rated and self-report)	To investigate the effect of adTMS delivered by a H1 coil to the left Dorsolateral Prefrontal Cortex (DLPFC), as an add-on treatment, on depressive symptoms in a sample of elderly patients with MDD.-measured by change in the 17 item Hamilton Depression rating Scale score. For a total score between 0 and 48, the higher the total score the more severe the depression. Response is reduction from baseline of ≥ 50% in the total score and remission is a total HAMD-17 score ≤ 7.; measured by change in the Beck-Inventory of Depression-II score. For a total score between 0 and 63, the higher the total score the more severe the depression. A score of ≤9 is the criterion for remission and BDI-II score decrease of 50% from baseline is the criterion for treatment response.; measured by change in the Geriatric Depression Scale 15 item version (GDS-15) self-rating scale score.	screening, Day 1 (+/-3d), Day 8 (+/-3d) ,Day 15 (+/-3d) Day 36 (+/-3d)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Clinical effect of tDCS 17 item Hamilton Depression rating Scale score	To investigate the effect of tdCS delivered by a Sooma tDCS to the left Dorsolateral Prefrontal Cortex (DLPFC), as an add-on treatment, on depressive symptoms in a sample of elderly patients with MDD.-measured by change in the 17 item Hamilton Depression rating Scale score. For a total score between 0 and 48, the higher the total score the more severe the depression. Response is reduction from baseline of ≥ 50% in the total score and remission is a total HAMD-17 score ≤ 7.	Day 15 (+/-3d) Day 36 (+/-3d)
Clinical effect of tDCS Beck-Inventory of Depression-II score	To investigate the effect of tdCS delivered by a Sooma tDCS to the left Dorsolateral Prefrontal Cortex (DLPFC), as an add-on treatment, on depressive symptoms in a sample of elderly patients with MDD.-measured by change in the Beck-Inventory of Depression-II score. For a total score between 0 and 63, the higher the total score the more severe the depression. A score of ≤9 is the criterion for remission and BDI-II score decrease of 50% from baseline is the criterion for treatment response.	Day 15 (+/-3d) Day 36 (+/-3d)
Clinical effect of tDCS Geriatric Depression Scale 15 item version (GDS-15) self-rating scale score	To investigate the effect of tdCS delivered by a Sooma tDCS to the left Dorsolateral Prefrontal Cortex (DLPFC), as an add-on treatment, on depressive symptoms in a sample of elderly patients with MDD.-measured by change in the Geriatric Depression Scale 15 item version (GDS-15) self-rating scale score. Score of ≤6 is the criterion for remission and decrease of 50% from baseline is the criterion for treatment response.	Day 15 (+/-3d) Day 36 (+/-3d)
maintenance effect of tDCS 17 item Hamilton Depression rating Scale score	To investigate the maintenance effect of tdCS delivered by a Sooma tDCS to the left Dorsolateral Prefrontal Cortex (DLPFC), as an add-on treatment, on depressive symptoms in a sample of elderly patients with MDD who responded to active adTMS measured by reduction from baseline of ≥ 50% in the total score in the 17 item Hamilton Depression rating Scale score. Maintenance effect occurs if the responders scores at day 15 remain or are lower on day 36.	Day 15 (+/-3d) Day 36 (+/-3d)
maintenance effect of tDCS Beck-Inventory of Depression-II score	To investigate the maintenance effect of tdCS delivered by a Sooma tDCS to the left Dorsolateral Prefrontal Cortex (DLPFC), as an add-on treatment, on depressive symptoms in a sample of elderly patients with MDD who responded to active adTMS measured by reduction from baseline of ≥ 50% in the total score in the BDI-II score decrease of 50% from baseline in the Beck-Inventory of Depression-II score. Maintenance effect occurs if the responders scores at day 15 remain or are lower on day 36.	Day 15 (+/-3d) Day 36 (+/-3d)
functional magnetic resonance imaging changes pre/post treatment in gender task as an incidental measure of emotional processing and probe of limbic function, and it's predictive value for response	To investigate if the fMRI gender task provides an incidental measure of emotional processing and could be a better probe of limbic function, and it's predictive value for response to adTMS and/or tDCS.To look for change post-pre intervention in the fMRI gender task response.	Day 1 (+/-3d), Day 8 (+/-3d)
effect on cognition MMSE	To investigate the effect of adTMS and tDCS on cognition as measured by increase in Mini Mental State examination scores.Scores range from 0 to 30, a score increase indicates improvement.	screening, Day 8 (+/-3d) ,Day 15 (+/-3d) Day 36 (+/-3d)
Incidence of Treatment-Emergent Adverse Events assessed with the Adverse Events questionnaire	To investigate the safety profile of adTMS and tDCS for elderly with MDD	Day 8 (+/-3d) ,Day 15 (+/-3d) Day 36 (+/-3d)
effect on suicide risk as measured by change in C-SSRS	To investigate the effect of adTMS and tDCS on suicide risk of elderly patients with MDD.	screening, Day 1 (+/-3d), Day 8 (+/-3d) ,Day 15 (+/-3d) Day 36 (+/-3d)
effect on suicide risk as measured by change in BSI	To investigate the effect of adTMS and tDCS on suicide risk of elderly patients with MDD.	screening, Day 1 (+/-3d), Day 8 (+/-3d) ,Day 15 (+/-3d) Day 36 (+/-3d)
effect on the gut microbiome	To investigate the effect of neurostimulation on the gut microbiome in elderly with MDD.	Day 1 (+/-3d), Day 8 (+/-3d) Day 36 (+/-3d)
possible neuroimaging biological markers for response	To investigate possible neurobiological markers for response to adTMS and/or tDCS by neuro imaging changes after adTMS and/or tDCS compared to baseline. Pre/Post changes in resting state fMRI en ASL (bloodflow) images.	Day 1 (+/-3d), Day 8 (+/-3d) Day 36 (+/-3d)

Collaborators and Investigators

• Sponsor: Universitair Ziekenhuis Brussel
• Investigators: Principal Investigator: Dieter Zeeuws, MD, Universitair Ziekenhuis Brussel

Study record dates

Study Major Dates

• Study Start (ACTUAL): May 7, 2021
• Primary Completion (ANTICIPATED): February 1, 2025
• Study Completion (ANTICIPATED): July 1, 2026

Study Registration Dates

• First Submitted: February 15, 2021
• First Submitted That Met QC Criteria: March 3, 2021
• First Posted (ACTUAL): March 5, 2021

Study Record Updates

• Last Update Posted (ACTUAL): November 3, 2022
• Last Update Submitted That Met QC Criteria: November 2, 2022
• Last Verified: November 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Mental Disorders; Mood Disorders; Depressive Disorder; Depressive Disorder, Treatment-Resistant
• Other Study ID Numbers: 2020/324

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: All data will be disclosed after publication
• IPD Sharing Time Frame: After publication of results
• IPD Sharing Access Criteria: research
• IPD Sharing Supporting Information Type: STUDY_PROTOCOL; SAP; ICF; ANALYTIC_CODE; CSR

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No